



#10 8/21/99  
T. Gray  
**PATENT**  
Docket No: 2026-4124US3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Kawakami, et.al.                      Group Art Unit: 1642  
Serial No. : 09/073,138                      Examiner: Johnson, N.  
Filed : May 5, 1998  
For : MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC  
AND THERAPEUTIC METHODS

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

RECEIVED  
TECH CENTER 1600/2900  
99 AUG 18 AM 10:55

**RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.111**

Sir:

In response to the Official Action dated May 13, 1999, applicants present the following amendment and remarks.

**IN THE CLAIMS**

Please amend the claims as follows.

29. (amended) A pharmaceutical composition comprising gp100 (SEQ ID NO: 27) or an immunogenic peptide [having] consisting essentially of 5-20 contiguous amino acids within the gp100 sequence and a pharmacologically acceptable excipient, diluent or carrier.

30. (amended) A method of treating melanoma in a mammal comprising administering a pharmaceutical composition comprising gp100 (SEQ ID NO: 27) or an immunogenic peptide [having] consisting essentially of 5-20 contiguous amino acids within